文献速递临床试验与 GCP

阿普司特治疗女性生殖器糜烂性扁平苔藓的随机安慰剂对照试验方案

Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial.
PubMed 文献 · Trials · 2021-07-20

本研究为随机、双盲、安慰剂对照临床试验,计划从挪威奥斯陆一家外阴专科门诊招募42例中重度生殖器糜烂性扁平苔藓成年女性,按1:1随机分配至阿普司特30mg每日两次组或安慰剂组治疗24周,主要终点为第24周平均GELP评分,旨在评估阿普司特在此类患者中的疗效与安全性。

要点

  • 阿普司特30mg每日两次治疗24周,主要终点为第24周平均GELP评分。
  • 允许合并使用外用糖皮质激素,次要终点包括疼痛VAS评分和外用激素用量。
  • 探索性终点包括外阴/阴道活检免疫组化变化。

核心结论

  • 该试验旨在评估口服阿普司特对女性生殖器糜烂性扁平苔藓的疗效与安全性。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验,计划招募42例中重度GELP成年女性,1:1随机分配至阿普司特30mg每日两次组或安慰剂组,治疗24周。

关键数值与推荐

  • 主要终点为第24周平均GELP评分(阿普司特组 vs 安慰剂组)。
  • 次要终点包括第0至24周平均GELP评分改善、患者报告的外用激素使用、疼痛视觉模拟评分及第16和24周GELP评分改善的患者数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Genital erosive lichen planus (GELP) is a genital subtype of lichen planus, a chronic autoimmune inflammatory disease of unknown aetiology. In women, GELP is characterised by painful vulvo-vaginal mucosal erosions and scarring, often resulting in poor sexual health and reduced quality of life. Treatment options are limited and often with little effect. Apremilast, a phosphodiesterase 4-inhibitor, has been shown to have a positive effect on psoriasis and other inflammatory skin diseases. We aim to investigate the effect and safety of peroral apremilast in women with GELP in a randomised placebo-controlled double-blinded clinical trial. METHODS: We will recruit 42 adult women with characteristic clinical and/or histological features of moderate-to-severe GELP from a specialised vulva clinic in Oslo, Norway. The patients will be randomised 1:1 to either apremilast 30 mg BID (with an initial dose titration on days 1-6) or a placebo for 24 weeks. The concomitant use of topical corticosteroids will be allowed. The primary end point will be the mean GELP score, a clinical scoring system, at week 24 in the apremilast-treated patients versus the placebo-treated patients. The secondary end points will include the mean GELP score improvement from weeks 0 to 24, patient-reported use of topical steroids, the pain score on a visual analogue scale and the number of patients with GELP score improvements at weeks 16 and 24. The Physician Global Assessment , Patient Global Assessment and selected quality of life and sexual function assessments will be recorded at weeks 0, 16 and 24. The exploratory endpoints include description of immunohistochemical changes before and after apremilast therapy, assessed in vulvar or vaginal biopsies at weeks 0 and 24. Regular follow-ups for possible adverse events will be conducted. DISCUSSION: The study design is based on experience from studies on apremilast in other inflammatory skin diseases using equivalent apremilast doses for approved indications. The trial may provide evidence for the use of apremilast in women with this burdensome genital dermatosis. TRIAL REGISTRATION: ClinicalTrials.gov NCT0365666 . Registered on 4 September 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Skullerud KH, Gjersvik P, Pripp AH, et al. Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial. Trials. 2021. PMID: 34284808. doi:10.1186/s13063-021-05428-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。